Online first
Clinical vignette
Published online: 2024-10-07
Early intervention prevented intrauterine fetus death due to placental abruption in woman with JAK2V617F mutation-positive essential thrombocythemia
1
, 1, 2, 3, 3, 2
, 1, 2, 3, 3, 2
DOI: 10.5603/gpl.101184
Pubmed: 39411819
Abstract
Not available
References
- Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer Journal. 2018; 8(2).
- Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007; 110(2): 485–489.
- Mancuso S, Accurso V, Santoro M, et al. The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors. Adv Hematol. 2020; 2020: 9124821.
- Edahiro Y. Treatment options and pregnancy management for patients with PV and ET. Int J Hematol. 2022; 115(5): 659–671.
- Ayres‐de‐Campos D, Spong C, Chandraharan E, et al. FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography. International Journal of Gynecology & Obstetrics. 2015; 131(1): 13–24.
